Abstract 275P
Background
Clinicopathological and molecular features of HR+/HER2- BC associated with response and survival following NACT or NET have been poorly characterized.
Methods
A total of 186 patients with early-stage HR+/HER2- BC treated with NACT (52.2%) and NET (47.8%) at the Hospital Clinic of Barcelona between 2014-2018 were evaluated. Associations with pathologic complete response (pCR), event-free survival (EFS) and overall survival (OS) were assessed with logistic and Cox regressions, where appropriate. Intrinsic subtypes (IS), risk of relapse (ROR) and selected genes’ expression before and after neoadjuvant treatment (NAT) were assessed with a research-based PAM50. SAM analyses were carried out. Significance was set at p≤0.05 and false discovery rate (FDR)≤5%.
Results
The pCR rates following NACT and NET were 18.6% and 3.4%, respectively. NACT (adjusted odds ratio [aOR]: 6.26, p=0.044) and non-Luminal IS (aOR: 8.89, p=0.021) were independently associated to pCR. Both NAT strategies reduced PgR and Ki67 levels significantly (p<0.001 all). After NAT, a significant (p<0.001) larger proportion of tumor samples were Luminal A/Normal-like (95.1% vs 55.3% at baseline) and ROR-low (78.8% vs. 22.9% at baseline). Both treatments induced the upregulation of selected immune genes and Basal-like-related genes/signature and downregulation of Luminal, proliferation and HER2-related genes/signatures (FDR<5% all). At a median follow-up of 64.0 months, 5-year EFS and OS were 90.4% and 95.0% with no significant difference based on NAT strategy (71.9% NET patients did not receive posterior CT). After adjusting for NAT cohort and significant factors at univariate analyses, including IS switch, only reduction of the proliferation signature remained significantly associated with better EFS (p=0.011) and OS (p=0.014). Similar results were observed with reduction of ROR for EFS (p=0.034), but not OS.
Conclusions
This study suggests that molecular downstaging induced by NACT or NET follows similar biological patterns and is associated with favorable survival outcomes, supporting molecular-driven neo-/adjuvant strategies, as tested in the ongoing RIBOLARIS phase II trial (NCT05296746).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
European Society for Medical Oncology (ESMO) through an ESMO Fellowship - Translational to Dr. Schettini.
Disclosure
F. Schettini: Financial Interests, Personal, Invited Speaker: Daiichi Sankyo, Gilead, Novartis; Financial Interests, Personal, Other, Travel expenses: Daiichi Sankyo, Gilead, Novartis. T. Pascual: Financial Interests, Personal, Invited Speaker: Pfizer/ AstraZeneca / Veracyte / Novartis; Financial Interests, Personal, Advisory Board: Roche/Genentech. M.J. Vidal Losada: Financial Interests, Personal, Advisory Board: Novartis/Pfizer, Roche, Pfizer, AstraZeneca/Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Novartis/Pfizer, Roche/Genentech, AstraZeneca/Daiichi Sankyo, Gilead Sciences; Financial Interests, Personal, Other, Travel, Accommodations, expenses: Pfizer; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Gilead Sciences. M. Munoz: Financial Interests, Personal, Advisory Board: Roche, Novartis, Pierre Fabre, Seagen, AstraZeneca; Financial Interests, Personal, Other, International conference travel grants: Roche, Pfizer, Lilly, Gilead. A. Prat: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker, Lecture fees: Novartis, Daiichi Sankyo; Financial Interests, Personal, Advisory Board, Advisory role/consultancy: Novartis, Pfizer, Oncolytics Biotech, Guardant Health, Peptomyc; Financial Interests, Institutional, Invited Speaker, Clinical trials: Daiichi Sankyo; Financial Interests, Institutional, Other, Contracted research: Boehringer Ingelheim, Medica Scientia inno. Research; Financial Interests, Personal, Advisory Board: AstraZeneca, 1TRIALSP, S.L.; Financial Interests, Personal, Member of Board of Directors, Leadership role: Reveal Genomics, SL.; Financial Interests, Personal, Stocks/Shares: Reveal Genomics, Oncolytics Biotech; Financial Interests, Personal, Royalties: Reveal Genomics, International Oncology Bureau, S.L.,; Financial Interests, Institutional, Local PI: Roche, AstraZeneca; Financial Interests, Personal and Institutional, Steering Committee Member: Daiichi Sankyo; Financial Interests, Institutional, Coordinating PI: Novartis; Non-Financial Interests, Institutional, Other, Leadership roles: Patronage committee: SOLTI Foundation, Actitud Frente al Cáncer Foundation; Non-Financial Interests, Personal, Other, Asociación Española de Investigación sobre el Cáncer: ASEICA. All other authors have declared no conflicts of interest.
Resources from the same session
294P - Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
Presenter: Tong Wei
Session: Poster session 02
295P - ESR1, PGR, ERBB2, MKI67 single gene analysis in neoadjuvant-treated early breast cancer patients
Presenter: Rebekks Spiller
Session: Poster session 02
296P - Identification of metabolism-related therapeutic targets to improve response to neoadjuvant chemotherapy in early breast cancers
Presenter: Françoise Derouane
Session: Poster session 02
297P - Prognostic and predictive impact of NOTCH1 in early breast cancer
Presenter: Julia Engel
Session: Poster session 02
298P - Association of luminal-androgen receptor (LAR) subtype with low HER2 in triple-negative breast cancer
Presenter: Lee Min Ji
Session: Poster session 02
299P - Single-cell transcriptomic analysis reveals specific luminal and T cell subpopulations associated with response to neoadjuvant therapy in early-stage breast cancer
Presenter: Xiaoxiao Wang
Session: Poster session 02
300P - Correlation of PD-L1 protein and mRNA expression and their prognostic impact in triple-negative breast cancer
Presenter: Kathleen Schüler
Session: Poster session 02
301P - Epigenetic modifications of IL-17 gene in patients with early breast cancer and healthy controls
Presenter: Ljubica Radmilovic Varga
Session: Poster session 02
302P - Clinicopathological features and outcomes of pregnancy associated breast cancer: Case control study -single institution experience
Presenter: Nashwa Kordy
Session: Poster session 02
303P - Differential prognostic role of PDGFRA alterations in breast cancer subtypes
Presenter: Panagiotis Vlachostergios
Session: Poster session 02